611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line

NurseWise 24-Hour Crisis Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Basic InformationLatest News
Scientists Report Progress on Genetic Test for Anal CancerLocation of Body Fat Can Indicate Obesity-Related Cancer RiskBlood Test for Earlier Detection of Pancreatic Cancer FeasibleSocial Contagion Impacts Imaging Use in Breast CancerNew Drug Approved for All Cancers With Genetic MarkerFDA OKs First Cancer Drug by Genetic Type, Not Organ of OriginBlood Test for Pancreatic Cancer Shows Early PromiseEven Small Amounts of Alcohol Can Affect Breast Cancer RiskSuicide Risk Quadruples After Lung Cancer Diagnosis3 Key Lifestyle Factors Can Lower Breast Cancer OddsBlacks More Prone to Colon Cancers That Arise Between Colonoscopies: StudyOne in Five Cancers in the United States Is Considered RareResearchers Say PDE5 Inhibitors Don't Cause MelanomaASCO: Capecitabine May Extend Survival in Biliary Tract CancerOverweight Boys Face Higher Colon Cancer Risk as AdultsYoga, Meditation May Ease Some Breast Cancer SymptomsMore U.S. Women Living With Metastatic Breast CancerASCO: Early Detection of Cancers Up Since Affordable Care ActHPV Vaccine May Also Prevent Cancers Affecting MenChemo Drug May Buy Time for Those With Bile Duct CancerMore U.S. Women Living Longer With Advanced Breast CancerToo Many Americans Still Go Without Cancer ScreeningsNuts! Good Medicine for Colon Cancer Survivors?AUA: E-Cigarettes Can Also Cause DNA Damage to Bladder MucosaE-Cigarettes Linked to Bladder Cancer RiskCould Tai Chi Ease Insomnia in Breast Cancer Survivors?Leukotriene B4 Is Promising Drug Target for Tx of LymphedemaNew VTE Often Occurs During Chemo in Ovarian CancerHope for 1st Drug Against Lymphedema, a Cancer ComplicationPoor Environmental Quality Tied to Higher Cancer RatesTraveling to Academic Hospital May Be Best for Pancreatic CancerNo Routine Screening for Thyroid Cancer: Expert PanelA Movie Instead of Anesthesia for Kids' Radiation TherapyAddressing Your Cancer RiskOsteoporosis Tx Ups Survival in Postmenopausal Breast CancerNot All Hospitals Equal When It Comes to Pancreatic Cancer CareGet Ready for Your 'Capsule Robot' Colon Cancer CheckCervical CA Survivors Often Have Long-Term Fatigue, InsomniaMore Side Effects With CRT Plus Metformin in Head, Neck CancerCervical Cancer May Leave Lasting Imprint on SurvivorsHousehold Income Takes a Hit After Cancer Diagnosis in SpouseLow-Dose Aspirin May Lower Risk for Common Breast Cancer by 20 PercentDrinking Boosts Breast Cancer Risk for Black Women, TooFDA Approves Kinase Inhibitor for Treatment of AMLRydapt Approved for Adults With Acute Myeloid LeukemiaRegorafenib Approved for Hepatocellular CarcinomaStivarga Approved for Liver CancerMoney Pressures Mount When a Spouse Gets CancerGene Expression Profile Improves ID of High-Risk MelanomaFDA Warns Companies Selling Fraudulent Cancer Treatments
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Chemo Drug May Buy Time for Those With Bile Duct Cancer

HealthDay News
Updated: May 18th 2017

new article illustration

THURSDAY, May 18, 2017 (HealthDay News) -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds.

People with bile duct cancer who received the medication lived for an average of about 17 months longer than those who didn't take it, the researchers found. Based on the findings, the study authors suggested that Xeloda should be given routinely to patients with this disease.

Bile duct cancer -- which occurs in an area that connects the liver, gallbladder and the small intestine -- is rare and aggressive. It affects an estimated 8,000 people in the United States each year, according to the American Cancer Society.

A statement from Cancer Research UK, which funded the new study, said it's difficult to study treatments for bile duct cancer because so few patients are available to take part in clinical trials.

For the study, researchers gave capecitabine (Xeloda) to about half of 450 bile duct cancer patients who underwent surgery. The other half underwent surgery but didn't get the drug.

The average survival after surgery for those who took the drug was 53 months compared to 36 months for those who only had surgery, the findings showed.

"While rare, bile duct cancer is difficult to treat and until recently there has been very little progress in treating the disease," said lead researcher John Primrose, of the University of Southampton in the United Kingdom.

"Our results clearly show that patients who have surgery should be given capecitabine, as a result of which more will survive and with few side effects," he said in a Cancer Research UK news release.

The findings are to be presented at the American Society of Clinical Oncology's annual meeting in Chicago in June. Research presented at medical meetings is considered preliminary until published in a peer-reviewed journal.

More information

For more about bile duct cancer, visit the American Cancer Society.